Novartis AG

Benchmarking vision-language models for diagnostics in emergency and critical care settings (2025) Kurz CF, Merzhevich T, Eskofier B, Kather JN, Gmeiner B Journal article Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study (2025) Albites-Sanabria J, Palumbo P, Bandinelli S, D’Ascanio I, Mellone S, Paraschiv-Ionescu A, Küderle A, et al. Journal article Assessment of Health-Related Quality of Life in Patients with Active Versus Inactive Adult-Onset Still’s Disease: Data from the PRO-AOSD Survey During the COVID-19 Pandemic (2025) Blank N, Andreica I, Rech J, Sözen Z, Feist E Journal article Evaluating the Divide Between Patients’ and Physicians’ Perceptions of Adult-Onset Still’s Disease Cases: Insights from the PRO-AOSD Survey (2025) Blank N, Andreica I, Rech J, Sözen Z, Feist E Journal article Magnetic Resonance Imaging Biomarkers of Knee Osteoarthritis Progression (2025) Collins JE, Mesenbrink P, Jin R, Dam EB, Deveza LA, Eckstein F, Guermazi A, et al. Journal article CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells (2025) Werner F, Wittner J, Lehmann C, Wahlbuhl-Becker M, Allabauer I, Hoffmann A, Schnell A, et al. Journal article Machine Learning Predictions of Overall and Progression-Free Survival in Advanced Breast Cancer (2025) Merzhevich T, Tanzanakis A, Salin E, Quiering C, Kurz C, Gmeiner B, Eskofier B Conference contribution Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article